Millions of Americans are not taking their GLP-1 drugs as prescribed

Feed excerpt — reported by Ars Technica

Cost and access barriers are pushing people to modified use and unapproved versions.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at Ars Technica →

View MAP Context →